Active Ingredient History
Ramucirumab is a fully human monoclonal antibody (IgG1) developed for the treatment of solid tumors. This drug was developed by ImClone Systems Inc. It was isolated from a native phage display library from Dyax. Wikipedia
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Adenocarcinoma (Phase 3)
Adolescent (Phase 2)
Bile Duct Neoplasms (Phase 2)
Biliary Tract Neoplasms (Phase 2)
Breast Neoplasms (Phase 3)
Carcinoid Tumor (Phase 2)
Carcinoma (Phase 2)
Carcinoma, Hepatocellular (Phase 3)
Carcinoma, Ovarian Epithelial (Phase 1)
Carcinoma, Renal Cell (Phase 2)
Carcinoma, Transitional Cell (Phase 3)
Child (Phase 2)
Cholangiocarcinoma (Phase 2)
Colonic Neoplasms (Phase 2)
Colorectal Neoplasms (Phase 3)
Desmoplastic Small Round Cell Tumor (Phase 1/Phase 2)
Drug Therapy (Phase 1/Phase 2)
Esophageal Neoplasms (Phase 3)
Esophagogastric Junction (Phase 2)
Fallopian Tube Neoplasms (Phase 2)
Gallbladder Neoplasms (Phase 2)
Glioblastoma (Phase 2)
Hamartoma (Phase 2)
Healthy Volunteers (Phase 1)
Intestinal Neoplasms (Phase 2)
Liver Neoplasms (Phase 1/Phase 2)
Lung Neoplasms (Phase 3)
Lymphoma, Mantle-Cell (Phase 1)
Melanoma (Phase 2)
Mesothelioma (Phase 2)
Mesothelioma, Malignant (Phase 2)
Mutation (Phase 2)
Neoplasm Metastasis (Phase 2)
Neoplasms ()
Ovarian Neoplasms (Phase 2)
Pancreatic Neoplasms (Phase 2)
Prostatic Neoplasms (Phase 2)
Rectal Neoplasms (Phase 2)
Sarcoma, Synovial (Phase 1/Phase 2)
Squamous Cell Carcinoma of Head and Neck (Phase 2)
Stomach Neoplasms (Phase 4)
Thymoma (Phase 2)
Ureteral Neoplasms (Phase 2)
Urethral Neoplasms (Phase 2)
Urinary Bladder Neoplasms (Phase 1)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue